Hangzhou Ruizhen Pharmaceutical

Hangzhou Ruizhen Pharmaceutical is a clinical-stage biotechnology company headquartered in Hangzhou, China, specializing in the development of next-generation small molecule drugs for oncology. Founded in 2021 by industry veterans with extensive experience in global pharmaceutical companies, Ruizhen focuses on targeting the RAS/MAPK signaling pathway to address unmet medical needs in cancer treatment. The company's lead candidate, RZ-001, is a highly selective SHP2 inhibitor currently in Phase 1 clinical trials for advanced solid tumors. Its broader pipeline includes inhibitors for KRAS G12C and SOS1, designed for both monotherapy and synergistic combination strategies. Ruizhen leverages structure-based drug design and medicinal chemistry to develop potent therapies for historically undruggable targets.